p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC.
Hideshima T, et al.
Oncogene. 2004 Nov 18;23(54):8766-76. doi: 10.1038/sj.onc.1208118.
Oncogene. 2004.
PMID: 15480425